MedTrace Logo

Natural Cycle Versus Hormone Replacement Therapy Cycle for a Frozen-thawed Embryo Transfer in PGT Patients

NCT03976544 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 362

Last updated 2025-01-28

No results posted yet for this study

Summary

The aim of the current study is to compare miscarriage rates (before 8 weeks) between a true natural cycle (awaiting spontaneous LH surge) and a hormone replacement therapy cycle prior to blastocyst transfer in preimplantation genetic testing (PGT) patients, with biopsy on day 5 of embryonic development. The advantage of performing the study in PGT patients is the exclusion of aneuploidy as a cause of miscarriage.

Conditions

  • Miscarriage
  • Frozen Embryo Transfer
  • Natural Cycle
  • Hormone Replacement Therapy Cycle
  • Preimplantation Genetic Screening
  • Euploid Embryos

Interventions

DRUG

Estradiol Valerate

Estradiol valerate will be started in the beginning of the menstrual cycle in order to induce proliferation of the endometrium.

DRUG

Micronized progesterone

If the endometrium is considered adequately proliferated, micronized progesterone is administered and frozen-thawed blastocyst transfer will take place on the 6th day of supplementation.

Sponsors & Collaborators

  • CRG UZ Brussel

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-25
Primary Completion
2025-01-01
Completion
2025-01-01

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03976544 on ClinicalTrials.gov